Publications by authors named "J Dalem"
Aims: Sodium-glucose co-transporter-2 (SGLT-2) inhibitor-induced weight loss might play a role in the debated elevated fracture risk with these agents. The aim of the current study was to investigate the association between SGLT-2 inhibitor use, changes in body mass index (BMI) and fracture risk.
Methods: A retrospective cohort study was conducted using data from the UK Clinical Practice Research Datalink (CPRD) GOLD (2013-2018).
Background And Aims: Thiazolidinediones (TZDs) and glucagon-like peptide-1 (GLP-1) receptor agonists are potential pharmacological treatment options for patients at risk of NAFLD. Therefore, we examined the association between the risk of NAFLD and the use of TZDs and GLP-1 receptor agonists compared with the use of sulfonylureas (SUs) and insulins. Additionally, we calculated the incidence of HCC in users of TZDs and GLP-1 receptor agonists.
View Article and Find Full Text PDFArticle Synopsis
- - The study aimed to explore patient-specific factors that affected changes in metformin treatment for type 2 diabetes patients before and after the 2015 NICE guidelines were introduced.
- - Analysis of data from a population-based cohort (2009-2016) showed that after the updated guidelines, there was a notable shift in prescribing patterns, with a decrease in sulphonylureas use and an increase in newer medications like DPP-4 and SGLT-2 inhibitors.
- - Findings suggest progress towards more personalized medication strategies, but indicate that some crucial factors influencing prescribing choices were not fully embraced by general practitioners even after the new guidelines were implemented.
We investigated the association between the current use of individual sulphonylureas and the risk of a first-ever acute myocardial infarction (AMI) and all-cause mortality, in a population-based cohort study, using primary care data from the Clinical Practice Research Datalink database (2004-2012). New users (N = 121 869), aged ≥18 years, with at least one prescription for a non-insulin antidiabetic agent were included. The first prescription defined start of follow-up.
View Article and Find Full Text PDFObjective: To determine the association between use of sulphonylureas and risk of hypoglycaemia in relation to renal function and sulphonylurea metabolic group compared with use of metformin.
Design: Population based cohort study using routinely collected data from general practices in England.
Setting: Clinical Practice Research Datalink (CPRD) database, 2004-12.